GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of PF-299804 (dacomitinib), a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutation.
Juan Manuel Sepúlveda
Research Funding - Pfizer
M. Angeles Vaz
No relevant relationships to disclose
Aurelio Hernandez-Lain
No relevant relationships to disclose
Miquel Gil
No relevant relationships to disclose
Pilar Sanhez
No relevant relationships to disclose
Ramos Ana
No relevant relationships to disclose
Oscar Gallego
No relevant relationships to disclose
Gaspar Reynes
No relevant relationships to disclose
Maria Victoria Bolós
Employment or Leadership Position - Pfizer
Raquel Luque
No relevant relationships to disclose
M. Quindos
No relevant relationships to disclose
Maria Martinez Garcia
No relevant relationships to disclose
Pedro Pérez Segura
No relevant relationships to disclose
Manuel Benavides
No relevant relationships to disclose
Carmen Balañá
No relevant relationships to disclose